Skip to content
Screener

Aclaris Therapeutics ACRS Financing Cash Flow

Financing Cash Flow at other companies

Incyte logo
IncyteINCY
$65.46M+682%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
$190.75M+68,268%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
$2.53M+314%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$410.21M+87,565%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$128.01M
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.47M+389%
Enterprise value$851.16M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs57,880
Payments of employee withholding taxes related to restricted stock unit award vesting(273)(284)
Proceeds from exercise of employee stock options and the issuance of stock265
Net cash provided by (used in) financing activities57,872(284)
Net (decrease) increase in cash and cash equivalents(793)832
Cash and cash equivalents at beginning of period19,96024,570
Cash and cash equivalents at end of period$19,167$25,402
Supplemental disclosure of non-cash investing activities:

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's financing cash flow?
Aclaris Therapeutics (ACRS) reported financing cash flow of $91K in Q2 2026.
How has Aclaris Therapeutics's financing cash flow changed year-over-year?
Aclaris Therapeutics's financing cash flow increased by 1111.1% year-over-year, from -$9K to $91K.
What is the long-term trend for Aclaris Therapeutics's financing cash flow?
Over 2 years (2022 to 2025), Aclaris Therapeutics's financing cash flow has grown at a -71.6% compound annual growth rate (CAGR), from $72.88M to -$5.86M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Aclaris Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude